Clinical Trials | December 17, 2024
Bayer announces positive topline resukts for Aflibercept 8 mg in phase III study
Demonstrates vision gains with extended treatment intervals in retinal vein occlusion
Demonstrates vision gains with extended treatment intervals in retinal vein occlusion
Till 30th November 2024, more than 2690 PACS have been given initial approval and 687 Kendras have been opened in PACS
Harnessing advanced data analysis for early detection, prevention and better outcomes
Final decision from the European Commission is anticipated within the coming months
The trademark rights for these brands will be transferred to Lupin by March next year.
Showing High Overall Response Rate (ORR) with durable responses and favorable safety profile in patients with heavily pretreated multiple myeloma
Aims to become India’s leading cancer testing company
Venus Remedies secures marketing authorization in Philippines
This strategic alliance is aimed at strengthening hospital systems and developing advanced AMR interventions
Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR
Subscribe To Our Newsletter & Stay Updated
